Using some of my previous examples re: Novartis and Pharming group NV
Partnership was done post P1 prior to P2 and still only had to give away low double digit to high double digit royalties. This was on a much, much smaller TAM & 1-3 possible indication drug.
I’m not convinced we would have to give away a high % of IP with such a large opportunity
20% of an FTO inhibitor has the potential to be worth multi billions per year. The cost to get it there is insignificant to the opportunity IMO
Using some of my previous examples re: Novartis and Pharming...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.000(0.00%) |
Mkt cap ! $281.0M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.70 | $1.65 | $81.29K | 48.99K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4500 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 1400 | 1 |
View Market Depth
| Last trade - 12.56pm 04/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |